|
Market Closed -
Nasdaq
21:00:00 19/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 33.87 USD | +4.38% |
|
-6.07% | -5.60% |
Company Valuation: Indivior Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,423 | 2,969 | 2,085 | 1,553 | 4,480 | 3,830 | - | - |
| Change | - | 22.54% | -29.76% | -25.5% | 188.39% | -14.51% | - | - |
| Enterprise Value (EV) 1 | 1,563 | 2,435 | 2,008 | 1,567 | 4,604 | 3,817 | 3,260 | 2,639 |
| Change | - | 55.81% | -17.52% | -21.95% | 193.72% | -17.09% | -14.61% | -19.04% |
| P/E | 12.8x | -57.2x | 1,527x | -34.5x | 21.9x | 8.72x | 7.9x | 7.23x |
| PBR | - | 59.3x | - | -8.02x | -45.8x | - | - | - |
| PEG | - | 0x | -15x | 0x | -0x | 0x | 0.8x | 0.77x |
| Capitalization / Revenue | 3.06x | 3.29x | 1.91x | 1.31x | 3.62x | 2.88x | 2.74x | 2.57x |
| EV / Revenue | 1.98x | 2.7x | 1.84x | 1.32x | 3.72x | 2.87x | 2.33x | 1.77x |
| EV / EBITDA | 7.74x | 10.8x | 6.97x | 4.64x | 10.8x | 5.24x | 4.12x | 3.07x |
| EV / EBIT | 8.36x | 11.5x | 7.47x | 5.02x | 11.1x | 5.54x | 4.42x | 3.32x |
| EV / FCF | 4.61x | -10.7x | -4.86x | -196x | -49.5x | 7.5x | 5.99x | 4.27x |
| FCF Yield | 21.7% | -9.32% | -20.6% | -0.51% | -2.02% | 13.3% | 16.7% | 23.4% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.35 | -0.38 | 0.01 | -0.36 | 1.64 | 3.72 | 4.105 | 4.49 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 791 | 901 | 1,093 | 1,188 | 1,239 | 1,332 | 1,400 | 1,489 |
| EBITDA 1 | 202 | 225 | 288 | 338 | 428 | 728.4 | 790.8 | 859.6 |
| EBIT 1 | 187 | 212 | 269 | 312 | 415 | 688.8 | 737.7 | 795.7 |
| Net income 1 | 205 | -53 | 2 | -48 | 210 | 474.3 | 530 | 582.9 |
| Net Debt 1 | -860 | -534 | -77 | 14 | 124 | -12.5 | -570 | -1,191 |
| Reference price 2 | 17.25 | 21.75 | 15.27 | 12.43 | 35.88 | 32.45 | 32.45 | 32.45 |
| Nbr of stocks (in thousands) | 140,437 | 136,489 | 136,551 | 124,970 | 124,854 | 118,014 | - | - |
| Announcement Date | 16/02/22 | 16/02/23 | 22/02/24 | 20/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 8.72x | 2.87x | 5.24x | - | 3.83B | ||
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | ||
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | ||
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | ||
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | ||
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | ||
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | ||
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | ||
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | ||
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | ||
| Average | 27.02x | 6.54x | 17.08x | 2.15% | 394.47B | |
| Weighted average by Cap. | 34.70x | 8.20x | 20.02x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- INDV Stock
- Valuation Indivior Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
















